A
A. Bowman
Researcher at Western General Hospital
Publications - 30
Citations - 791
A. Bowman is an academic researcher from Western General Hospital. The author has contributed to research in topics: Breast cancer & Metastatic breast cancer. The author has an hindex of 14, co-authored 29 publications receiving 726 citations. Previous affiliations of A. Bowman include Edinburgh Cancer Research Centre.
Papers
More filters
Journal Article
CA125 Response Is Associated with Estrogen Receptor Expression in a Phase II Trial of Letrozole in Ovarian Cancer: Identification of an Endocrine-sensitive Subgroup
TL;DR: The results imply that letrozole treatment can produce disease stabilization and CA125 responses that in turn are linked to higher levels of ER expression, suggesting the presence of an endocrine-sensitive group that could be targeted in future studies.
Journal ArticleDOI
Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours.
Chris Twelves,Klaas Hoekman,A. Bowman,Jan B. Vermorken,A. Anthoney,John F. Smyth,C. van Kesteren,Jos H. Beijnen,J. Uiters,Jantien Wanders,J. Gomez,Cecilia Guzman,J. Jimeno,A. Hanauske +13 more
TL;DR: Yondelis (ET-743) is a novel anticancer agent isolated from the marine ascidian Ecteinascidia turbinata that possesses potent antitumour activity and a novel mechanism of action at the level of gene transcription.
Journal ArticleDOI
Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04).
Robert E. Coleman,Michelle Collinson,Walter M Gregory,Helen Marshall,Richard Bell,D. Dodwell,M. Keane,M. Gil,Peter Barrett-Lee,Diana Ritchie,A. Bowman,Victoria Liversedge,R De Boer,José Luís Passos-Coelho,S. O'Reilly,Gianfilippo Bertelli,Johnathan Joffe,Janet E. Brown,Caroline Wilson,Juan-Carlos Tercero,Joël Jean-Mairet,Roger R. Gomis,David Cameron +22 more
TL;DR: Disease benefits with adjuvant ZOL in postmenopausal early breast cancer persist at 10 years of follow-up, and the biomarker MAF identified a patient subgroup that derived benefit from ZOL irrespective of menopausal status.
Journal ArticleDOI
Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study.
Charlotte van Kesteren,Chris Twelves,A. Bowman,Klaas Hoekman,Luis Lopez-Lazaro,Jose Jimeno,Cecilia Guzman,Ron A. A. Mathôt,Andrew Simpson,Jan B. Vermorken,John F. Smyth,Jan H.M. Schellens,Michel J.X. Hillebrand,Hilde Rosing,Jos H. Beijnen +14 more
TL;DR: Hepatic and hematological toxicities correlated with exposure to ET-743, and the percentage decrease in platelets, white blood cells and neutrophils correlated with the area under the plasma concentration versus time curve, dose and maximal plasma concentration.
Journal ArticleDOI
TELEMAM: A cluster randomised trial to assess the use of telemedicine in multi-disciplinary breast cancer decision making
Ian Kunkler,Robin J Prescott,Robert J. Lee,J A Brebner,John Cairns,R G Fielding,A. Bowman,G Neades,A Walls,Udi Chetty,J.M. Dixon,M. Smith,T Gardner,M. Macnab,S Swann,Justine MacLean +15 more
TL;DR: Telemedicine delivered breast cancer multi-disciplinary meetings have similar clinical effectiveness to standard 'in-person' meetings.